Financial support and resources available for businesses impacted by COVID-19.

Support for businesses impacted by COVID-19.

Thrasos Therapeutics

Thrasos is a private, clinical‑stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company has two major programs; its lead program targets acute kidney injury (AKI) while the second program addresses diabetic nephropathy, a leading cause of chronic kidney disease (CKD).

Investment year: 2015
Industry sector: Drugs
Region: Quebec
Website

Recent news

2016-02-29

Thrasos Announces Promising Results for Phase 2 THR-184 Dose Ranging Clinical Study for the Prevention of Acute Kidney Injury (AKI)

Learn More
View All News

Certain news link to external sites and are presented in French only.